Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca examining impact of new COVID variant on vaccine, antibody cocktail

11/26/2021 | 01:38pm EST

LONDON, Nov 26 (Reuters) - AstraZeneca said on Friday it was examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on its vaccine and its antibody cocktail, adding it was hopeful its combination drug would retain efficacy.

The World Health Organization (WHO) on Friday designated a new COVID-19 variant B.1.1.529, detected in South Africa with a large number of mutations, as being "of concern".

AstraZeneca has distributed 2 billion doses of its vaccine worldwide, although rollout of the shot was paused in South Africa in February after it was shown to offer minimal protection against mild to moderate illness caused by the Beta variant, which was dominant in the country at the time.

"As with any new emerging variants, we are looking into B.1.1.529 to understand more about it and the impact on the vaccine," AstraZeneca said in a statement, adding it was conducting research in Botswana and Eswatini to collect data.

"That will enable us to collect real world data of Vaxzevria against this new virus variant."

The Anglo-Swedish pharmaceutical firm emphasised that the vaccine has been shown to be effective against all SARS-CoV-2 variants of concern.

AstraZeneca said that it had developed a vaccine platform to respond quickly to new variants with Oxford University, where the vaccine was created. It has previously said it is working on a variant vaccine to better target the Beta variant.

The company has also developed an antibody cocktail which can be used both to prevent and to treat COVID-19.

Although some scientists have expressed concern that the spike protein mutations might hinder the effectiveness of monoclonal antibody drugs, the combination drug made by AstraZeneca might retain its efficacy, the company said.

"We are also testing our long-acting antibody combination AZD7442 against this new variant and are hopeful AZD7442 will retain efficacy since it comprises two potent antibodies with different and complementary activities against the virus," it said.

(Reporting by Alistair Smout; Editing by Kevin Liffey, Elaine Hardcastle)

ę Reuters 2021
All news about ASTRAZENECA PLC
07:50aSAP to buy U.S. fintech Taulia; eyes metaverse opportunities
01/25Valneva Includes Booster Shots in Late-Stage Study of COVID-19 Jab
01/25Valneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
01/25Germany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
01/25Egetis appoints Karl Hård as Head of Investor Relations and Communication
01/24PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies
01/24AstraZeneca's Rare Progressive Disease Drug Granted US FDA Orphan Drug Tag
01/24Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 228 M - -
Net income 2021 2 276 M - -
Net Debt 2021 24 734 M - -
P/E ratio 2021 57,4x
Yield 2021 2,46%
Capitalization 177 B 178 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,57x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 114,21 $
Average target price 139,09 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-2.27%177 586
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303